AbbVie (ABBV) announced that Health Canada has approved MAVIRET for the treatment of acute and chronic hepatitis C virus infection in adults and pediatric patients 3 years of age and older and weighing = 12 kg. The company noted that Canadian healthcare providers are now empowered to start treatment for acute HCV as soon as the diagnosis is made.
MAVIRET is a pan-genotypic, once-daily, ribavirin-free treatment that combines glecaprevir, an NS3/4A protease inhibitor, and pibrentasvir, an NS5A inhibitor, dosed once-daily as three oral tablets.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.